Clinical trials: Dryness of Mouth
Dry Eye, Sjogren's Syndrome
Pilot Study for Testing Safety of Repetitive Magnetic Stimulation for Treatment of Dry Eye
The study aims to test the safety of Repetitive Magnetic Stimulation (RMS) treatment for dry eye disease. Patients are asked to undergo a one-time treatment with Epitech Ocular Magnetic Stimulation Device on one eye in the first…
- Conditions
- Dry Eye, Sjogren's Syndrome, Aqueous Tear Deficiency, Meibomian Gland Dysfunction
- Trial name
- NCT03012698
- Testing
- Ocular Repetitive Magnetic Stimulation (RMS) treatment
- Where
- 3 sites in Israel
- Volunteers
- 29 people
- Sponsor
- Epitech Mag Ltd.
Healthy, Sicca Syndrome
A Longitudinal, Observational Biomarker Study in Participants With Primary Sjogren's Syndrome
The main objective of the study is to characterize the gene expression in immune and epithelial cells in salivary gland biopsy samples and blood of pSS (primary Sjögren's syndrome) and non-pSS participants including healthy…
- Conditions
- Healthy, Sicca Syndrome, Sjögren's Syndrome
- Trial name
- NCT02422407
- Testing
- Biopsy
- Where
- 4 sites in United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Biogen
Dry Eye, Evaporative Dry Eye Disease
Microbiome-Focused Food Supplement for Evaporative Dry Eye Due to Meibomian Gland Dysfunction
Dry eye disease (DED) is a common chronic condition characterized by ocular surface discomfort and tear film instability. Evaporative DED associated with meibomian gland dysfunction (MGD) is a frequent phenotype and is often…
- Conditions
- Dry Eye, Evaporative Dry Eye Disease, Meibomian Gland Dysfunction (Disorder)
- Trial name
- NCT07453212
- Testing
- Dietary Supplement: Microbiome-targeted oral supplement
- Where
- 3 sites in Turkey (Türkiye)
- Volunteers
- 130 people
- Sponsor
- Varol TUNALI
Polio, Measles
the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L Vaccines
This study evaluated the antibody persistence of Chinese children five years after they received four doses of sIPV, two doses of MMR vaccine and one dose of HepA-L vaccine.
- Conditions
- Polio, Measles, Rubella, Mumps
- Trial name
- NCT07338851
- Where
- 6 sites in China
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited
Diabetes Mellitus, Type 2
A Clinical Trial Comparing The Efficacy And Safety Of 2 Different Initial Dose Prescriptions For Exubera.
The primary objective of this study is to assess whether a simple initial dose prescription of inhaled insulin (Exubera) achieves glycemic control (HbA1c) after 16 weeks that is non-inferior compared to the standard weight-based…
- Trial name
- NCT00437489
- Testing
- Inhaled Human Insulin (Exubera)
- Where
- 9 sites in Hong Kong, Pakistan and 2 more
- Volunteers
- 49 people
- Sponsor
- Pfizer
Dry Socket
Impact of Treatment With ALVEOGYL in Patients With Post-extraction Dry Socket
Alveogyl (Septodont, Saint-Maur-des-Fossés - France) is a Medical Device used as dressing in case of dry socket. ALVE study is a clinical investigation measuring Alveogyl performance and safety in patients with post-extraction…
- Trial name
- NCT05536115
- Testing
- Alveogyl
- Where
- 16 sites in France, India
- Volunteers
- 120 people
- Sponsor
- Septodont
Dry Mouth
Bioequivalency Study of 5 mg Piolocarpine Tablets Under Fed Conditions
The objective of this study was the bioequivalence of a Roxane Laboratories' Pilocarpine Tablets, 5 mg, to SALAGEN® Tablets, 5 mg (MGI Pharma) under fed conditions using a single-dose, 2-treatment, 2-period, crossover design.
- Trial name
- NCT00601211
- Testing
- Pilocarpine
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Roxane Laboratories
Sjogren's Syndrome
Safety and Efficacy Study of Subcutaneous Belimumab and Intravenous Rituximab Co-administration in Subjects With Primary Sjogren's Syndrome
This study is a multi-national, multi-center, double-blind (sponsor open), randomized, placebo-controlled trial in subjects with active primary Sjögren's syndrome designed to understand the safety and tolerability profile of…
- Trial name
- NCT02631538
- Testing
- Belimumab, Rituximab
- Where
- 36 sites in Argentina, Canada and 8 more
- Volunteers
- 86 people
- Sponsor
- GlaxoSmithKline
Dry Mouth
Crossover Bioequivalence Study of Cevimeline 30 mg Capsules Under Fasted Conditions
The objective of this study was to prove the bioequivalence of Roxane Laboratories' Cevimeline 30 mg under fasted conditions
- Trial name
- NCT01903122
- Testing
- Cevimeline
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Roxane Laboratories
Sjogren's Syndrome (SS)
An Efficacy and Safety Study of Injectable Ravagalimab to Assess Change in EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) in Adult Participants With Moderately to Severely Active Primary Sjogren's Syndrome (pSS)
Sjogren's syndrome (SS) is a chronic, multisystem autoimmune disease characterized by lacrimal and salivary gland inflammation, with resultant dryness of the eyes and mouth and occasional glandular enlargement.
- Trial name
- NCT05217472
- Testing
- Ravaglimab, Ravagalimab
- Where
- Netherlands
- Sponsor
- AbbVie
Dental Plaque, Pus Collection
Regular Antibacterial Photodynamic Therapy on Oral Hygiene in Elderly Residents
Around 40 people will participate in the study. The study participants will be recruited from service homes in the City of Helsinki. The subjects will be randomized into two groups.
- Conditions
- Dental Plaque, Pus Collection, Oral Disease, Dryness Oral
- Trial name
- NCT05853679
- Testing
- Lumoral Treatment, Standard oral hygiene instructions according to the Finnish Dental Association
- Where
- Finland
- Volunteers
- 31 people
- Sponsor
- Koite Health Oy
Sjögren's Syndrome
Exosomes in Patients With Ocular Involvement of Sjögren's Syndrome
This study is a single-center, multiple-dosing, prospective, nonrandom, single-arm trial.
- Trial name
- NCT07192666
- Testing
- Exosome Preparation
- Volunteers
- 12 people
- Sponsor
- Guangdong ProCapZoom Biosciences Co., Ltd.